Ultra-Early Differential Diagnosis of Acute Cerebral Ischemia and Hemorrhagic Stroke by Measuring the Prehospital Release Rate of GFAP

Author:

Mattila Olli S1,Ashton Nicholas J2345,Blennow Kaj26,Zetterberg Henrik2678ORCID,Harve-Rytsälä Heini9,Pihlasviita Saana1,Ritvonen Juhani1,Sibolt Gerli1,Nukarinen Tiina1,Curtze Sami1,Strbian Daniel1ORCID,Pystynen Mikko9,Tatlisumak Turgut1011,Kuisma Markku9,Lindsberg Perttu J1ORCID

Affiliation:

1. Neurology and Clinical Neurosciences, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

2. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

3. Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden

4. Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK

5. NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK

6. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

7. Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, UK

8. UK Dementia Research Institute at UCL, London, UK

9. Emergency Medicine and Services, Department of Emergency Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

10. Department of Clinical Neuroscience/Neurology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

11. Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden

Abstract

Abstract Background Plasma glial fibrillary acidic protein (GFAP) and tau are promising markers for differentiating acute cerebral ischemia (ACI) and hemorrhagic stroke (HS), but their prehospital dynamics and usefulness are unknown. Methods We performed ultra-sensitivite single-molecule array (Simoa®) measurements of plasma GFAP and total tau in a stroke code patient cohort with cardinal stroke symptoms [National Institutes of Health Stroke Scale (NIHSS) ≥3]. Sequential sampling included 2 ultra-early samples, and a follow-up sample on the next morning. Results We included 272 cases (203 ACI, 60 HS, and 9 stroke mimics). Median (IQR) last-known-well to sampling time was 53 (35–90) minutes for initial prehospital samples, 90 (67–130) minutes for secondary acute samples, and 21 (16–24) hours for next morning samples. Plasma GFAP was significantly higher in patients with HS than ACI (P < 0.001 for <1 hour and <3 hour prehospital samples, and <3 hour secondary samples), while total tau showed no intergroup difference. The prehospital GFAP release rate (pg/mL/minute) occurring between the 2 very early samples was significantly higher in patients with HS than ACI [2.4 (0.6–14.1)] versus 0.3 (−0.3–0.9) pg/mL/minute, P < 0.001. For cases with <3 hour prehospital sampling (ACI n = 178, HS n = 59), a combined rule (prehospital GFAP >410 pg/mL, or prehospital GFAP 90–410 pg/mL together with GFAP release >0.6 pg/mL/minute) enabled ruling out HS with high certainty (NPV 98.4%) in 68% of patients with ACI (sensitivity for HS 96.6%, specificity 68%, PPV 50%). Conclusions In comparison to single-point measurement, monitoring the prehospital GFAP release rate improves ultra-early differentiation of stroke subtypes. With serial measurement GFAP has potential to improve future prehospital stroke diagnostics.

Funder

Sigrid Juselius foundation

Jane and Aatos Erkko foundation

HUS governmental research grants

Finnish Medical Foundation

Maire Taponen Foundation

Wallenberg Scholar supported by grants from the Swedish Research Council

the European Research Council

Swedish State Support for Clinical Research

Centrum för Idrottsforskning

The Alzheimer Drug Discovery Foundation

AD Strategic Fund and the Alzheimer's Association

Olav Thon Foundation, the ErlingPersson Family Foundation, Stiftelsen för Gamla Tjänarinnor

Hjärnfonden

European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie

UK Dementia Research Institute

Swedish Research Council

Swedish Alzheimer Foundation

Swedish state under the agreement between the Swedish government and the County Councils

University of Gothenburg

Sahlgrenska University Hospital

Sigrid Juselius Foundation

Wennerström Foundation

European Union

Bayer

Boehringer Ingelheim

Bristol Myers Squibb

BrainsGate

Pfizer

Portola Pharma. S. Pihlasviita is supported by Maire Taponen Foundation

The Finnish Medical Foundation, and The Biomedicum Helsinki Foundation

Publisher

Oxford University Press (OUP)

Subject

Biochemistry, medical,Clinical Biochemistry

Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3